Drugs / BGM1812
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07294235 | Dec 2025 → Mar 2026 overdue | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07224399 | Oct 2025 → May 2026 overdue | obesity disorder | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGM1812 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07294235 ↗ |
| Route | Subcutaneous | “Single ascending doses of BGM1812 administered subcutaneously (SC).” NCT07224399 ↗ |